Background and Aims: Real-world patients' medication adherence and inhalation techniques severely impact asthma clinical and economic outcomes, but have not been incorporated into previous asthma costeffectiveness models. Advancements in smart, digital and eHealth-based inhalers development could offer new opportunities. This study aims to develop a model incorporating adherence and inhalation technique and determine the potential cost-effectiveness of adherence and inhalation technique enhancing interventions.
Background and Aims: Real-world patients' medication adherence and inhalation techniques severely impact asthma clinical and economic outcomes, but have not been incorporated into previous asthma costeffectiveness models. Advancements in smart, digital and eHealth-based inhalers development could offer new opportunities. This study aims to develop a model incorporating adherence and inhalation technique and determine the potential cost-effectiveness of adherence and inhalation technique enhancing interventions.
Methods: A Markov model with 6 health-states which consists of combinations of 2 asthma control status (controlled vs uncontrolled) along with 2 mortality states (asthma-related vs other cause) and exacerbation states (i.e. oral-corticosteroid burst, emergency department visit, and hospitalization) was developed for simulating the cost-effectiveness of adherence and inhalation improvement programs for patients with uncontrolled asthma. Bi-weekly health state transitions were used along with a lifetime horizon to determine the incremental cost-effectiveness ratio of three hypothetical scenarios (1. full adherence/good technique 2. full adherence/poor technique and 3. poor adherence/good technique) vs usual care (poor adherence/poor technique) within the U.S. payer perspective.
Results: Over a 60-year period, the full adherence and good technique group was associated with (discounted) $107, 309 costs and 18.82 quality-adjusted life years (QALYs), the full adherence and poor technique group was associated with $107,936 costs and 18.80 QALYs, the poor adherence and good technique group was associated with $106,517 costs and 18.74 QALYs, and the poor adherence and technique group was associated with $103,667 costs and 18.74 QALYs. The incremental cost-effectiveness ratio of the full adherence good technique (full adherence poor technique and poor adherence good technique) vs usual care was $41,831 ($66,826 and $1,056,016) per QALY.
Conclusion:
Given the growing development of adherence and inhalation technique improving interventions (e.g. smart inhalers) in asthma, this study shows that attempts in improving adherence and inhalation technique for uncontrolled asthma patients can be associated with significant gains in QALYs at the standard willingness-to-pay threshold. Background and Aims: Omalizumab is a monoclonal anti-IgE antibody that has been shown to be an effective add-on therapy in severe allergic asthma (SAA). However, there is little information about its clinical benefit among Malaysian patients. This descriptive study was sought to review real-life outcomes and safety of omalizumab in SAA.
Methods: We performed a retrospective review to assess pulmonary function (FEV1), asthma control by the ACT score and GINA classification, medication use and 'hospital exacerbation' in 12 patients who were treated with omalizumab at Hospital Raja Perempuan Zainab II for SAA. 'Hospital exacerbation' included emergency department visit and /or hospitalization due to exacerbation of bronchial asthma. Information was collected from medical records during follow up from 12-month pre and postomalizumab initiation periods.
Results: All the 12 patients were classified as uncontrolled asthma (GINA), received high dose inhaled corticosteroid and long-acting β (2)-agonists prior to treatment with omalizumab. Nine (75%) patients were female, average age of 42.1+/-13.3 year and allergic rhinitis was the commonest comorbidity (41.7%). The mean serum total IgE level was 921.4 IU/ML. The mean duration of omalizumab treatment was 2.5 years.
At 4 months; the ACT score increased significantly from 12.3 to 19.3 (P<0.001), oral corticosteroid requirement showed significant reduction from 58.3% to 8.3% and the GINA score improved to 58.3% ( partially controlled asthma) and only 39.1% ( uncontrolled asthma). The improvement sustained significantly for one year with multiple significance tests and Bonferroni correction. At 6 months, the mean FEV1 increased significantly from 56.0% to 69.8% (P<0.026). The mean hospital exacerbations reduced from 3 to 0.73 exacerbations per year using paired t test (P<0.001) with no side effects reported by patients.
Omalizumab is beneficial and safe as add-on therapy for SAA. In the setting of limited resource, local data on real-life outcomes and cost effectiveness of omalizumab therapy warrants further study.
